A Randomized, Parallel, Open-Label Study to Compare Once-Daily Sevelamer Carbonate Powder Dosing With Thrice-Daily Sevelamer Hydrochloride Tablet Dosing in CKD Patients on Hemodialysis

2010 ◽  
Vol 55 (2) ◽  
pp. 307-315 ◽  
Author(s):  
Steven Fishbane ◽  
James Delmez ◽  
Wadi N. Suki ◽  
Srinivas K. Hariachar ◽  
Jeremy Heaton ◽  
...  
Keyword(s):  
Open Label ◽  
Once Daily ◽  
Open Label Study ◽  
Label Study ◽  
Sevelamer Hydrochloride ◽  
Sevelamer Carbonate

scholarly journals Fosamprenavir plus Ritonavir Increases Plasma Ketoconazole and Ritonavir Exposure, while Amprenavir Exposure Remains Unchanged

2007 ◽  
Vol 51 (8) ◽  
pp. 2982-2984 ◽  
Author(s):  
Mary B. Wire ◽  
Charles H. Ballow ◽  
Julie Borland ◽  
Mark J. Shelton ◽  
Yu Lou ◽  
...  
Keyword(s):  
Steady State ◽  
Healthy Subjects ◽  
Open Label ◽  
Time Curve ◽  
Once Daily ◽  
Open Label Study ◽  
Label Study ◽  
Concentration Time

ABSTRACT Plasma ketoconazole (KETO), amprenavir (APV), and ritonavir (RTV) pharmacokinetics were evaluated in 15 healthy subjects after being treated with KETO at 200 mg once daily (QD), fosamprenavir (FPV)/RTV at 700/100 mg twice daily (BID), and then KETO at 200 mg QD plus FPV/RTV at 700/100 mg BID in this open-label study. The KETO area under the concentration-time curve at steady state was increased 2.69-fold with FPV/RTV. APV exposure was unchanged, and RTV exposure was slightly increased.

ADHD Treatment With Once-Daily OROS Methylphenidate: Final Results From a Long-Term Open-Label Study

2005 ◽  
Vol 44 (10) ◽  
pp. 1015-1023 ◽  
Author(s):  
Timothy Wilens ◽  
Keith MCBurnett ◽  
Mark Stein ◽  
Marc Lerner ◽  
Thomas Spencer ◽  
...  
Keyword(s):  
Open Label ◽  
Once Daily ◽  
Open Label Study ◽  
Label Study ◽  
Adhd Treatment
Sign in / Sign up

Export Citation Format

Share Document